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Influence of Infectious Disease on Ceftiofur Pharmacokinetics and the relative 
risk of violative residues in cattle  
 




Mastitis is a growing problem that is occurring with cattle in the United States, and it is 
primarily a debilitating problem for the dairy industry. As the demand for these products 
grows, the number of large herd sizes has been increasing. It is a very debilitating 
disease that causes inflammation of the mammary tissue that can cause permanent 
damage to the animal and cause it to become unproductive. This disease can be spread 
through cross-contamination of milking equipment because of its bacterial origin, 
wreaking havoc throughout a herd quickly. A common antibiotic for the treatment of 
this disease is Ceftiofur. It is revered for being a safe antibiotic that minimizes 
withdrawal time and leaves no milk residue, therefore reducing milk waste. Recently, 
society has become more aware of agricultural practices, and antibiotic residues in 
animal products are becoming a hot topic across many social groups. Studies are being 
done to look deeper into the issue and look at differences between the 





Antibiotics are an incredibly valuable 
asset to the livestock industry to 
manage and treat bacterial infections, 
and a common one of these is 
Ceftiofur. This particular medication is 
a beta-lactamase, broad spectrum, 
third-generation cephalosporin 
antibiotic. It works by binding and 
inactivating penicillin-binding 
proteins, also known as PBPs, which 
are located on the inner membrane of 
a bacterial cell wall. When the 
antibiotic inactivates these proteins, it 
interferes with the cross-linking of 
peptidoglycan that is necessary for the 
bacterial cell wall (Ceftiofur). The 
interference causes a weakening of 
the cell wall and the cell is lysed 
(Ceftiofur). There are a couple of 
different forms of this antibiotic 
including Ceftiofur hydrochloride and 
Ceftiofur sodium. Ceftiofur 
hydrochloride, for example, Excenel 
®, can be used to treat different 
bacterial diseases across several 
species, but in cattle, it is indicated to 
be used in the treatment of bovine 
respiratory disease, shipping fever, 
pneumonia that are associated with 
the bacteria Mannheimia haemolytica, 
Pasturella multocida, and Histophilus 
somni (Zoetis, 2013).  It can also be 
used in the treatment of acute 
interdigital necrobacillosis, also 
known as foot rot and is another 
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common occurrence in the cattle 
industry. It is best used for foot rot 
when it is associated with the bacteria 
Fusobacterium necrophorum and 
Bacteroides malaninogenicus (Zoetis, 
2013). Ceftiofur hydrochloride is also 
used in the treatment of acute metritis 
(Zoetis, 2013), which can happen up 
to 14 days postpartum generally. 
According to label direction, cattle 
that are treated with Excenel ® 
should not be taken to slaughter for 
four days after the last treatment with 
the drug, however, there is not any 
evidence of milk residues and there 
should not be any milk loss resulting 
from the drug being used with dairy 
cattle (Zoetis, 2013).  
There is another form of Ceftiofur that 
is known as Ceftiofur sodium, which 
has a broader species spectrum than 
the Ceftiofur hydrochloride 
mentioned previously. Along with 
cattle and swine, this antibiotic has 
equine, canine, and ovis uses. A 
commercial example of this is 
Naxcel®.  Recently, consumers have 
become more concerned about the 
presence of antibiotics in their meat 
and dairy products. This ever-growing 
fear of contaminated food has sparked 
an interest in making sure that the 
animal products produced by the 
agricultural industry are indeed safe 
for consumption. A critical step in 
food safety is that if an animal is 
treated with medication, that the 
producer follows an appropriate 
withdrawal time that is required for 
the medication to leave the animals 
system entirely. In the case of 
Ceftiofur sodium, when used in cattle, 
there is not a specified withdrawal 
time when it is used according to label 
directions; in fact, Naxcel is self-
proclaimed to be the first antibiotic 
with “zero milk discard.” (Naxcel 
(Ceftiofur Sodium) sterile powder ). 
The lack of a withdrawal time is true 
for both slaughter cattle as well as 
dairy cattle. However, many of the 
studies that have looked into the 
elimination kinetics of Ceftiofur have 
used healthy animals for their 
experiments. It is important to note 
because animals clear drugs from 
their systems differently when they 
are diseased versus when they are 
healthy. The instances of Ceftiofur 
being the cause of violative residues in 
cattle have been on the rise and are 
becoming a more significant cause for 
concern within the livestock 
community, with violations in both 
meat and milk. Pharmacokinetics 
looks into how drugs move through 
the body (Mochel, 2018). It is a 
process by which a drug is absorbed, 
distributed, metabolized and excreted 
from the body. The concentrations of 
these drugs are generally measured in 
the blood plasma, which provides an 
average drug exposure from the entire 
body (Mochel, 2018). The liver and 
kidney are critical organs in the 
clearance of medications from the 
body. Drugs with a low FU (fraction of 
drug unbound in the plasma) tend to 
be cleared by the liver while drugs 
with a high FU tend to be cleared by 
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the kidney (Mochel, 2018). A common 
issue in the cattle industry, especially 
with dairy cattle, is animals being 
infected with mastitis. Mastitis is an 
inflammation of the mammary gland 
that is usually a response to a 
bacterial infection. The inflammation 
response causes the mammary tissues 
to be damaged that can become 
permanent without treatment (Dairy, 
2018). This disease can cause a 
financial impact on producers because 
of its reduction in milk yield and it 
causing an increase of cull rates 
because of damage to the tissues from 
the disease making the animals no 
longer productive (Dairy, 2018). 
Several studies that have been used in 
this review look further into the 
clearance of Ceftiofur from diseased 
cattle, and to further investigate the 
differences in clearance of this 
antibiotic in a diseased bovine when 




The consumer demand for dairy 
products has been on the rise, and in 
the past several years, the United 
States dairy industry has gone 
through a variety of changes to 
compensate for growing demand. One 
of these changes is that the number of 
larger herds across the country. In a 
study performed in 2013, they looked 
at 50 farms to characterize clinical 
mastitis that occurs in large dairy 
herds in Wisconsin (Oliveira, Hulland, 
& Ruegg, 2013).  To participate in this 
study, the herd was required to have a 
minimum of 200 lactating cows, to 
participate in monthly DHI testing, 
they were required to use a 
computerized system for record 
keeping, use a specific milking routine 
that included fore-stripping quarters 
for mastitis detection, and they had to 
use antimicrobial pharmaceuticals for 
treatment of infected cows (Oliveira, 
Hulland, & Ruegg, 2013). If a farm met 
all of these criteria, staff participating 
in the study then visited the farm, and 
each farm was instructed to enroll the 
next 17 cows that presented with 
clinical mastitis in their herd. When 
looking at presenting cows, they did 
not discriminate between levels of 
severity of the disease. As soon as 
cows presented with mastitis, they 
were given treatment and milk 
samples were collected from 
presentation until 14 to 21 days after 
the treatment ended. The samples 
were taken from each infected quarter 
of the mammary gland and then used 
for microbiological analysis. The 
treatments prescribed to the animals 
were based on individual farm 
protocol that was already in place. 
After treatment was ended, they took 
follow up data until 90 days after 
enrolment. The collected milk was 
analyzed for the presence of microbial 
pathogens, and out of the 741 cases 
analyzed, the most common 
pathogens were Escherichia coli, 
which was present in 22.5% of the 
cases. The second most common was 
an environmental streptococcus, 
which was present in 12.8% of the 
cases (Oliveira, Hulland, & Ruegg, 
2013). The study concluded that 
environmental pathogens are one of 
the major causes of clinical mastitis in 
dairy cattle. By looking at milk and 
bacterial analysis, they determined 
that the characteristics and clinical 
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outcomes of animals presenting with 
this disease were mostly dependent 
on the disease-causing pathogen. 
Roughly 30% of the collected samples 
resulted in no microbial growth. It 
was stated that more studies need to 
be conducted in order to understand 
further and better manage these 
cases. Through bacterial analysis, it 
was also found that Staphylococcus 
aureus was not a significant 
contributor to clinical cases of mastitis 
in Wisconsin because there were only 
a few cases that isolated this 
organism. While doing the 90-day 
follow-up, it was observed that cattle 
that experienced disease due to gram-
negative bacteria were more likely to 
revert to a disease state from mastitis. 
One-third of these animals infected 
with the gram-negative organisms 
were affected by severe symptoms. 
Animals that were infected with gram-
positive bacteria were more likely to 
have mild to moderate symptoms. 
(Oliveira, Hulland, & Ruegg, 2013). 
The overall goal of this study was to 
understand better which specific 
pathogens caused different levels of 
disease to understand better and set 
up more pathogen-specific treatment 
programs.  (Oliveira, Hulland, & 
Ruegg, 2013) 
Dr. Patrick Gorden has made several 
contributions to this area of research, 
with mastitis of dairy cattle being his 
disease model of choice. In a study 
performed in 2016, Dr. Gorden and his 
fellow researchers had a hypothesis 
that disease plays a role in the 
pharmacokinetics of Ceftiofur 
hydrochloride (CEF) and was a cause 
of the violative residues being found 
upon inspection. Dr. Gorden and a 
team took eight cows with naturally 
occurring mastitis and eight clinically 
healthy cows from the Iowa State 
University dairy farm. They treated 
both the control and the diseased 
group with 2.2 mg of Ceftiofur 
hydrochloride per kilogram of body 
weight once a day for five consecutive 
(Gorden P. J., et al., 2016) 
(Gorden P. J., et al., 2016) 
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days by intramuscular administration. 
They then collected blood from the 
animals at time points 0, 0.33, 0.67, 1, 
1.5, 2, 3, 4, 8, 16 and 24 hours after the 
first injection of the CEF. They also 
took samples every eight hours 
afterward until 120 hours after the 
final dose of the antibiotic. The plasma 
was separated from the blood sample 
and was analyzed by liquid 
chromatography along with mass 
spectrometry looking at CEF 
concentrations. At every time point, 
except for zero, the team was able to 
detect Ceftiofur hydrochloride in the 
plasma samples. They found that the 
plasma harvested from the diseased 
group of cattle contained a much 
higher concentration of CEF in their 
plasma after the first injection, and 
then a lower concentration from 
hours 40-152 after the first 
administration of Ceftiofur. These 
results were put into a single-dose 
noncompartmental PK model, which 
indicated that the diseased group had 
a shorter plasma half-life. When the 
diseased cattle were compared to the 
control cattle, it was found that the 
diseased group initially had a higher 
peak concentration and a higher 
volume of distribution and drug 
clearance rates. The plasma obtained 
from the diseased group of cattle also 
showed a lower area under the curve 
per dosing interval, a steading-state 
concentration maximum, and dose-
adjusted peak steady-state 
concentration. When compared to the 
control group, it was determined at all 
other PK parameters were the same 
between the two groups. It was 
concluded that altered 
pharmacokinetics could be playing a 
role in the differences between the 
plasma concentrations between the 
two groups. This alteration could be 
causing an issue of violative residues 
in meat, but more research was 
needed to make a reliable connection 
between the two. (Gorden P. J., et al., 
2016)  
This research led to a study 
performed in 2017, also by Dr. 
Gorden, that looked at the 
pharmacokinetics of Ceftiofur 
hydrochloride when given with 
flunixin meglumine, more commonly 
known as Banamine. Flunixin 
meglumine is a very common 
nonsteroidal anti-inflammatory 
medication (NASAID) that is used in 
both cattle and horses. It is used to 
reduce fevers and inflammation that 
occur with a variety of conditions 
(Merck Animal Health, 2018). There is 
a withdrawal time for flunixin. The 
label states that cattle should not be 
slaughtered for consumption within 
four days of the animal’s last 
treatment. In dairy cattle, milk from a 
treated animal must not be used for 
human consumption until 36 hours 
after the last treatment (Merck Animal 
Health, 2018). Banamine and Ceftiofur 
are both approved for use in dairy and 
beef cattle, and in conjunction with 
each other during treatment (Gorden 
P. J., et al., 2017). Interestingly enough, 
both Ceftiofur and Banamine are the 
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most popular drugs of choice from 
their respective drug categories 
(Gorden P. J., et al., 2017). This study 
was interested in determining if the 
pharmacokinetics of flunixin 
meglumine, when administered 
intravenously, or Ceftiofur 
hydrochloride, when administered 
intramuscularly, would show different 
pharmacokinetics when administered 
in conjunction compared to when they 
are administered as individual doses. 
For their treatment groups, ten 
healthy cows from the Iowa State 
University dairy farm were utilized; 
they did not have a disease group for 
this experiment. The study used a 
three-period, three-treatment 
crossover design. All the cows were 
given each medication on time and 
were then given a ten-day washout 
period between the treatments. After 
the treatment period ended, samples 
of plasma and interstitial fluid were 
taken and stored for analysis. Plasma 
microfiltrate was also collected from 
each cow and was then put through 
microcentrifugation to look at the 
plasma protein binding of each of the 
medications. To determine drug 
concentrations in the samples, they 
were analyzed using high-pressure 
liquid chromatography, which was 
coupled with mass spectrometry. The 
results showed that when flunixin and 
Ceftiofur are co-administered, 
interactions between the two do not 
occur. Dr. Gorden concluded in his 
paper that more studies need to be 
done to determine further if these 
results are still valid in cattle infected 
with a disease (Gorden P. J., et al., 
2017). This goes back to the previous 
study performed in 2016 that 
indicated that cattle in a diseased state 
have altered pharmacokinetics and 
pass drugs out of their system at a 
different rate (Gorden P. J., et al., 
2016).  
Following the 2017 study, Dr. Gorden 
recently published another study this 
year that looked into 
comparing the plasma 
and interstitial fluid pharmacokinetics 
and tissue residues of cattle infected 
with coliform mastitis that were 
treated with Ceftiofur crystalline-free 
acid. There were several objectives 
that the team set to accomplish in this 
study. The first was to determine the 
absolute bioavailability of Ceftiofur 
crystalline-free acid (CFA) in healthy 
cows when compared to cattle that 
were diseased. They also compared 
the plasma and interstitial fluid 
pharmacokinetics and plasma protein 
binding of the drug between the two 
groups of cattle. The last goal of the 
study was to determine the Ceftiofur 
residue profile in tissues of diseased 
cattle (Gorden, et al., 2018). Unlike the 
study performed in 2016, which had 
cattle collected with naturally 
occurring mastitis (Gorden P. J., et al., 
2016), the cattle for this study that 
were selected for the disease group 
were induced with  
mastitis using an intramammary 
Escherichia coli infusion (Gorden, et 
al., 2018). After mastitis was induced, 
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the cattle were treated 
with Ceftiofur CFA.  
It was found that there 
was not a significant 
effect of treatment, but 
the treatment-by-time 
interaction was 
significant. There was a 
much higher 
concentration of the drug 
in the plasma of the 
diseased cows at the T2 
hour, T12 and T16. For 
the diseased cows, an 
analysis showed that the 
terminal half-life was 
much longer when 
compared to a healthy  
group as well as the 
volume of distribution 
during the elimination of the drug was 
much higher in the diseased cows. The 
results also showed that there was no 
difference in the plasma protein 
binding of Ceftiofur and interstitial 
fluid pharmacokinetics (Gorden, et al., 
2018). 
 Another difference with this study, 
when compared to the 2016 paper, 
was that the cattle used in this 
experiment were sacrificed at the end 
of the trial. The kidneys of the 
sacrificed animals showed that none 
of the cattle had any residues of 
Ceftiofur in their kidney that was 
above the stated tolerance level in the 
United States (Gorden, et al., 2018).  
The kidneys were studied after the 
animals had gone through a required 
withdrawal period.  Upon talking to 
Dr. Gorden, he stated that he wishes 
that they had sacrificed the cattle used 
in the previous study to look at 
residues in the inner organs. The 
cattle in that study were much sicker 
than these cattle, and he thinks that 
the results would have been 
fascinating. The 2018 study concluded 
that the results did not support their 
hypothesis that diseased cattle needed 
a longer withdrawal time after 
treatment with Ceftiofur; however, 
there were alterations in the terminal 
half-life of the drug that suggests this 
idea is theoretically possible (Gorden, 
et al., 2018). 
(Gorden, et al., 2018) 
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There was a study performed in 2002 
that looked into the efficacy of 
intramuscularly administered 
Ceftiofur to lactating dairy cows with 
clinical mastitis, to reduce the 
incidences of mastitis related death 
and culling. They took 104 dairy cows 
that were diagnosed with clinical 
mastitis and randomly assigned the 
cows to two different treatment 
groups. In one group, the cows were 
given 2.2mg/kg of Ceftiofur through 
an intramuscular injection. This 
dosage was repeated every 24 hours 
for five doses of the drug. The second 
group of cows was the control group 
and did not receive any antibiotic 
intervention of their disease. 
However, both treatment groups did 
receive an intramammary injection of 
pirlimycin (Erskine, Bartlett, 
VanLente, & Phipps, 2002). Pirlimycin 
hydrochloride is used for the 
treatment of clinical and subclinical 
mastitis in lactating cattle. It is used in 
response to mastitis caused by 
Staphylococcus and Streptococcus 
bacteria. This antibiotic is the only 
FDA-approved antibiotic on the 
market that is approved for treating 
mastitis. (Zoetis Services LLC, 2018). 
The Pirlimycin was given in each 
mammary quarter every 24 hours for 
three doses. It was also noted that 
each cow in the trial was initially 
given fluids and anti-inflammatory 
drugs as supportive therapies and 
these therapies varied from farm to 
farm. The anti-inflammatory used was 
flunixin meglumine, also known as 
Banamine. At the conclusion of the 
study, it was determined that 14 out 
of 104 cases (13.5%) the cow ended 
up either dying or was culled. Out of 
51 cows that were treated with 
Ceftiofur, 4 of them or 7.8% were lost 
(Erskine, Bartlett, VanLente, & Phipps, 
(Gorden, et al., 2018). 
(Gorden, et al., 2018) 
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2002). 53 cows were not treated with 
antibiotics and out of those ten were 
lost. 56 cows were positive for a 
coliform organism upon culture, and it 
was found that those cases produced a 
higher loss rate than the cows that 
were not infected with a coliform 
organism (Erskine, Bartlett, VanLente, 
& Phipps, 2002). Out of the infected 14 
of the animals were lost when 
compared to the zero that was lost out 
of the 48 unaffected animals. When 
looking into the treated versus control 
groups, however, there were 27 cows 
in the control group that were affected 
with coliforms, and 10 of them were 
considered lost because of death or 
culling. In the treated group, there 
were 29 animals infected with 
coliform organisms, and four of them 
were considered losses (Erskine, 
Bartlett, VanLente, & Phipps, 2002). 
After analysis of the results, it was 
concluded that an intramuscular 
injection of Ceftiofur did not affect the 
outcome of cattle infected with severe 
clinical mastitis when all etiologic, or 
disease-causing factors, were included 
in the analysis. They did, however, 
conclude that when a dairy cow 
suffers from severe clinical mastitis as 
the result of coliform organisms, that 
therapy with Ceftiofur reduced the 
proportion of cases that resulted in 
the loss of an animal from either death 
or culling (Erskine, Bartlett, VanLente, 






Mastitis is a growing problem that is 
occurring with cattle in the United 
States, and it is primarily a debilitating 
problem for the dairy industry. As the 
demand for these products grows, the 
number of large herd sizes has been 
increasing. It is a very debilitating 
disease that causes inflammation of 
the mammary tissue that can cause 
permanent damage to the animal and 
cause it to become unproductive. This 
disease can be spread through cross-
contamination of milking equipment 
because of its bacterial origin, 
wreaking havoc throughout a herd 
quickly. A common antibiotic for the 
treatment of this disease is Ceftiofur. 
It is revered for being a safe antibiotic 
that minimizes withdrawal time and 
leaves no milk residue, therefore 
reducing milk waste. Recently, society 
has become more aware of 
agricultural practices, and antibiotic 
residues in animal products are 
becoming a hot topic across many 
social groups. Studies are being done 
to look deeper into the issue and look 
at differences between the 
pharmacokinetics of a diseased animal 
when compared to a healthy one.  
These studies primarily looked at 
Ceftiofur because of its common usage 
and overall safety claim. Previously, 
safety studies of this antibiotic were 
performed using healthy cattle, and 
because animals in a diseased state 
excrete pharmaceuticals differently, it 
was essential to include animals 
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infected with a disease. By looking at 
plasma and other biological samples, 
it was determined that although the 
idea that Ceftiofur can be excreted 
slower from a cow infected with 
mastitis increasing the frequency of 
violative residues, the results did not 
show a prominent difference between 
healthy cows and those infected with 
mastitis. More studies need to be 
performed in the future to look 
further into this issue. It is also 
essential to further investigate how 
other antibiotics work in this model 
system including diseased cattle. 
Although most violations in cattle are 
the result of Ceftiofur residues, with 
the ever-growing trend of society 
being concerned about antibiotics in 
their food, it would be interesting to 
look more into other common 
antibiotics. Also, Ceftiofur is not only 
used in dairy cattle. It is also critical 
for therapy of swine, beef cattle, 
sheep, and horses. Although horses 
are not used as a meat source in the 
United States, it would be interesting 
to look into the elimination kinetics of 
horses as well as the other species it is 
approved for. Looking at residues in 
more species would give a broader 
idea of safety across species barriers 
and give a broader picture of the 
residues left behind from Ceftiofur in 
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